SPECIAL FEATURES

CCR Translations

6061 Harnessing Immune Responses in the Tumor Microenvironment: All Signals Needed
Dung T. Le and Elizabeth M. Jaffee
See related article, p. 6286

6064 Test-Firing Ammunition for Spliceosome Inhibition in Cancer
Scott M. Dehm
See related article, p. 6296

CCR Perspectives in Drug Approval

6067 Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary

Molecular Pathways

6074 Molecular Pathways: Adipose Inflammation as a Mediator of Obesity-Associated Cancer
Louise R. Howe, Kothe Subbaramaiah, Clifford A. Hudis, and Andrew J. Dannenberg

6084 Molecular Pathways: Induction of Polyploidy as a Novel Differentiation Therapy for Leukemia
Diane S. Krause and John D. Crispino

Review

6089 Lessons Learned from Radiation Oncology Clinical Trials
Fei-Fei Liu, for the workshop participants, Paul Okunieff, Eric J. Bernhard, Helen B. Stone, Stephen Yoo, C. Norman Coleman, Bhadrasain Vikram, Martin Brown, John Buatti, and Chandan Guha

HUMAN CANCER BIOLOGY

6101 Semaphorin 4F as a Critical Regulator of Neuroepithelial Interactions and a Biomarker of Aggressive Prostate Cancer
Yi Ding, Dandan He, Diego Florentin, Anna Frolov, Sue Hilsenbeck, Michael Ittmann, Dov Kadmon, Brian Miles, David Rowley, and Gustavo Ayala

6112 Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

6126 Hypoxic Activation of the PERK/eIF2α Arm of the Unfolded Protein Response Promotes Metastasis through Induction of LAMP3
Hilda Mujic, Anika Nagelkerke, Kasper M.A. Roushop, Stephen Chung, Naz Chaudary, Paul N. Span, Blaise Clarke, Michael Milosevic, Jenny Sykes, Richard P. Hill, Marianne Koritzinsky, and Bradley G. Wouters

CANCER THERAPY: PRECLINICAL

6138 Adrenomedullin Blockade Suppresses Growth of Human Hormone–Independent Prostate Tumor Xenograft in Mice
Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model
Aizea Morales-Kastresana, Miguel F. Samman, Hesam E. Rodriguez, Asis Palazon, Ivan Martinez-Forero, Sara Labiano, Sandra Hervas-Stubb, Bruno Sangro, Carmen Ochoa, Ana Rouzaut, Arantxa Arquile{l}a Cueto, Elizabet Bolan{l}os, Maria Jure-Enkel, Ines G{u}{e}tgemann, and Ignacio Melero

Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer
Maxwell N. Skor, Erin L. Wonder, Masha Kocherginsky, Anju Goyal, Ben A. Hall, Yi Cai, and Suzanne D. Conzen

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
Takeshi Shimamura, Zhao Chen, Margaret Soucheray, Julian Carretero, Eiki Kikuchi, Jeremy H. Tchaicha, Yandi Gao, Katherine A. Cheng, Travis J. Cohoon, Jun Qi, Esra Akbay, Alec C. Kimmelman, Andrew L. Kung, James E. Bradner, and Kwok-Kin Wong

Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: An Optimal Delivery of siRNA and Anticancer Drug
Vatsal Shah, Oleh Taratula, Olga B. Garbuzenko, Eleni R. Taratula, Lorna Rodriguez-Rodriguez, and Tamara Minko

Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model
Andressa Ardiani, Benedetto Farsaci, Connie J. Rogers, Andy Pottier, Zhimin Guo, Thomas K. King, David Apelian, and James W. Hodge

Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
Sara A. Flanagan, Todd M. Pitts, Timothy P. Newton, Gillian N. Kulikowski, Aik Choon Tan, Martine C. McManus, Anna Spreafico, Maria I. Kachiaeva, Heather M. Selby, John J. Tentler, S. Gail Eckhardt, and Stephen Leong

JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2{\textsuperscript{V617F}}-Driven Disease
Emeline Evrot, Nicolas Ebel, Vincent Romanet, Claudia Roelli, Rita Andraos, Zhiyan Cai, Arno Dilemeyer, Ernesto Dammassa, Dario Sterker, Robert Cozens, Francesco Hofmann, Masato Murakami, Fabienne Baffert, and Thomas Radimerski

Molecular Chaperone gp96 Is a Novel Therapeutic Target of Multiple Myeloma
Yunpeng Hua, Shai White-Gilbertson, Joshua Kellner, Saleh Bachidi, Saad Z. Usmani, Gabriela Chiosis, Ronald DePinho, Zilha Li, and Bei Liu

Associations between Single-Nucleotide Polymorphisms in the PI3K–PTEN–AKT–mTOR Pathway and Increased Risk of Brain Metastasis in Patients with Non–Small Cell Lung Cancer
Qianxia Li, Ju Yang, Qianqian Yu, Huanlei Wu, Bo Liu, Huilun Xiong, Guangyuan Hu, Jing Zhao, Xinglin Yuan, and Zhongxing Liao

Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma
Ignacio I. Wistuba, Carmen Behrens, Francesca Lombardi, Susanne Wagner, Junya Fujimoto, M. Gabriela Raso, Lorenzo Spaggiari, Domenico Galletta, Rohyn Riley, Elisha Hughes, Julia Reid, Zaina Sangale, Steven G. Swisher, Neda Kalhor, Cesar A. Moran, Alexander Gutin, Jerry S. Lanchbury, Massimo Barberis, and Edward S. Kim
Promoter Hypomethylation of EpCAM-Regulated Bone Morphogenetic Protein Gene Family in Recurrent Endometrial Cancer

Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia
Mauricio Burotto, Maryalice Stelter-Stevenson, Evgeny Arons, Hong Zhou, Wyndham Wilson, and Robert J. Kreitman

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
See related article, p. 6061

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
Ferry A.L.M. Eskens, Francisco J. Ramos, Herman Burger, James P. O'Brien, Adelaida Pierea, Maja J.A. de Jonge, Yoshikazu Mizui, Erik A.C. Wiemer, Maria Josepa Carreras, Jose Baselga, and Josep Tabernero
See related article, p. 6064

Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
Robert J. Cardnell, Ying Feng, Lixia Diao, You-Hong Fan, Fatemah Masrourpour, Jing Wang, Yuqiao Shen, Gordon B. Mills, John D. Minna, John V. Heymach, and Lauren A. Byers

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Letter

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Response
Klaus G. Griewank, Henrike Westekemper, Bastian Schilling, Elisabeth Livingstone, Tobias Schimming, Antje Sucker, Uwe Hillen, Klaus-Peter Steuhl, Lisa Zimmer, and Dirk Schadendorf
ABOUT THE COVER

Cellular internalization of siRNA (red fluorescence) delivered by the nanocarrier (green fluorescence) specifically targeted to cancer cells. Superimposition of red (siRNA) and green (nanocarrier) fluorescence images gives yellow color. For details, see the article by Shah and colleagues on page 6193 of this issue.